HLAVNÍ TÉMA Orální semaglutid – Rybelsus®, první agonista GLP-1 receptoru pro perorální použití v klinické praxi | 95 / Vnitř Lék. 2022;68(2):89-95 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 11. Zinman B, Aroda VR, Buse JB et al. PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care 2019;42:2262-2271. 12. Mosenzon O, Blicher TM, Rosenlund S et al. PIONEER 5 Investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo‑controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019; 7:515-527. Erratum in: Lancet Diabetes Endocrinol 2019;7:e21. 13. Rosenstock J, Allison D, Birkenfeld AL et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019; 321:1466-1480. 14. Buse JB, Bode BW, Mertens A, Cho YM et al. PIONEER 7 investigators. Long‑term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open‑label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care 2020;8:e001649. 15. Rodbard HW, Rosenstock J, Canani LH et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 2019;42:2272-2281. 16. Pratley R, Amod A, Hoff ST et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019;394:39-50. 17. Husain M, Birkenfeld AL, Donsmark M et al. PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841-851. 18. Marso SP, Bain SC, Consoli A et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844. 19. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206. 20. Sharma A, Verma S. Mechanisms by Which Glucagon‑Like‑Peptide-1 Receptor Agonists and Sodium‑Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. Can J Diabetes. 2020;44:93-102. 21. Rakipovski G, Rolin B, Nøhr J et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci 2018;3:844-857. 22. Buse JB, Wexler DJ, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43:487-493. 23. Dahl K, Brooks A, Almazedi F et al. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. Diabetes Obes Metab 2021;23:1594-1603. 24. Hjerpsted JB, Flint A, Brooks A et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first‑hour gastric emptying in subjects with obesity. Diabetes Obes Metab 2018;20:610-619. 25. Vergès B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab 2017; 43 Suppl 1:2S3-2S12. Pro více informací pište a volejte: dokoupilova@solen.cz, 585 209 206 Lazecká 297/51, 779 00 Olomouc, www.solen.cz Chystáte se vydat knihu? Svěřte ji SOLENu ZAJISTÍME VÁM: > kvalitní redakční a editorskou práci > recenze > grafiku a tisk > publicitu (včetně elektronické verze)
RkJQdWJsaXNoZXIy NDA4Mjc=